Scientists create personalized antibodies to attack stage IV cancer
NCT ID NCT06674538
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests whether antibodies made from a patient's own tumor can safely target and help destroy cancer cells. Researchers take blood and tumor samples to create custom antibodies that recognize unique markers on the cancer cells. The antibodies are then given through infusions to 12 adults with stage IV cancers that have not responded to prior treatments. The main goal is to check safety, not yet to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- custom-made chimeric antibodies
- What this could lead to
- If it works, this could point toward a personalized treatment for advanced cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 12 people, so it is mainly checking safety, not effectiveness. The antibodies are made individually, which is complex and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.